Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 6.26M P/E - EPS this Y 47.40% Ern Qtrly Grth -
Income -13.23M Forward P/E -0.47 EPS next Y 7.60% 50D Avg Chg -15.00%
Sales 5.51M PEG - EPS past 5Y - 200D Avg Chg -49.00%
Dividend N/A Price/Book 2.20 EPS next 5Y - 52W High Chg -86.00%
Recommedations 2.00 Quick Ratio 0.45 Shares Outstanding 5.90M 52W Low Chg 24.00%
Insider Own 2.27% ROA -69.39% Shares Float 5.75M Beta 0.67
Inst Own 11.56% ROE - Shares Shorted/Prior 52.69K/83.45K Price 2.44
Gross Margin -96.46% Profit Margin -240.15% Avg. Volume 32,904 Target Price 32.75
Oper. Margin -289.05% Earnings Date Oct 29 Volume 5,619 Change -2.40%
About PLUS THERAPEUTICS, Inc.

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

PLUS THERAPEUTICS, Inc. News
11/22/24 Plus Therapeutics to Present Positive FORESEE Clinical Trial Summary Demonstrating Utility of CNSide™ Cerebrospinal Fluid Assay in Diagnosis and Clinical Management of Patients with Leptomeningeal Metastases
11/21/24 Plus Therapeutics to Present Multi-Institutional Experience Using the CNSide™ Cerebrospinal Fluid Assay in Patients with Leptomeningeal Metastases
11/17/24 Plus Therapeutics Third Quarter 2024 Earnings: Beats Expectations
11/15/24 Plus Therapeutics Inc (PSTV) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ...
11/14/24 Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
11/13/24 ProPhase Labs, Inc. (PRPH) Reports Q3 Loss, Tops Revenue Estimates
11/12/24 Organogenesis (ORGO) Tops Q3 Earnings and Revenue Estimates
11/06/24 Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership
11/05/24 Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024
11/04/24 Zoetis (ZTS) Q3 Earnings and Revenues Beat Estimates
10/29/24 Plus Therapeutics Showcases Leptomeningeal Metastases Programs at the 2024 SNO Annual Meeting in Houston, Texas
10/01/24 Plus Therapeutics Reports ReSPECT-GBM Clinical Trial Update at the 2024 Congress of Neurological Surgeons Annual Meeting
09/18/24 Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of Neurological Surgeons Annual Meeting
09/04/24 Plus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
08/17/24 Plus Therapeutics Second Quarter 2024 Earnings: Beats Expectations
08/15/24 Q2 2024 Plus Therapeutics Inc Earnings Call
08/14/24 Plus Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
08/13/24 Plus Therapeutics Presents Positive Clinical Trial Results at the 2024 SNO/ASCO CNS Metastases Conference
08/12/24 Plus Therapeutics Presents Positive Interim ReSPECT-LM Phase 1 Data for Leptomeningeal Metastases at 2024 SNO/ASCO CNS Metastases Conference
08/08/24 Plus Therapeutics to Announce Second Quarter Financial Results and Host Conference Call on August 14, 2024
PSTV Chatroom

User Image BossTrade Posted - 1 hour ago

$PSTV Company looks like it may have potential. The only red flag I see is $1M in cash. I would wait for an offering. Imo

User Image kwintz Posted - 1 day ago

$PSTV lower lows and lower highs every week. Sub $1 is coming before the delisting or reverse split. Have a good weekend

User Image kwintz Posted - 1 day ago

$PSTV 👇 been pumping about radiopharmaceutical acquisitions since 2022 while pstv has decreased 70% since then. Clearly there is 0 interest in this ticker. Beware of the serial pumpers.

User Image Zaneyone Posted - 1 day ago

$PSTV Japanese candlestick chart with upcoming major catalyst list attached below. Yes, I am the same guy who predicted major gains in SMMT & RIGL just before they skyrocketed. PSTV could easily be the next DRUG and spikes up rapidly (very low float of 5.75M) when amateur SS are forced to buy to cover, especially on Fridays! Folks, PSTV is a keeper aka American Dream stock to buy, hold & accumulate. Page 3, 4, & 5 of investor presentation https://ir.plustherapeutics.com/static-files/b4cfa441-60a4-4c20-b6e4-3228c0cc8505 are particularly interesting for bulls.

User Image Zaneyone Posted - 1 day ago

$PSTV $XBI $BBI $SLS XBI is rebounding well from that massive SS attack because big pharma is hunting smaller biotech/pharma Co. for the most lucrative M&A opportunities to serve as growth catalysts (big pharma's MB$ patents are expiring). Huge news PR & Start of MM$/month sales for PSTV = Strong Buy! https://ir.plustherapeutics.com/news-releases/news-release-details/plus-therapeutics-present-positive-foresee-clinical-trial PSTV is one of the best remaining M&A/MM$ partnership targets out there because it's going commercial in Q4 per recent Q3 PR for investors with CNSide Cancer Detecting Test for 3 types cancer. Rev for 2024 should be at least $9-$10M, but starting in Q1 we can expect MM$/month. This test is best of breed. PSTV execs told us they would submit a new medical device application to FDA for Rhenium 188 Nanospheres for Liver Cancer in Q1 2025. That will be approved by end of Q2 & generate more MM$ rev/month + PSTV has a MB$ pipeline + $3.9M more grant rev incoming in Dec. + ideal buyout candidate (see investor presentation) + low float + new med. device = 5-10 x gains!

User Image Robbaland Posted - 1 day ago

$PSTV writing these posts just a few hours before the crucial and highly anticipated presentations scheduled for the weekend means doing everything to steal your money until the last moment. BEWARE OF KWINTZ..

User Image kwintz Posted - 1 day ago

$PSTV dilution hitting hard + naked shorts stacking the ask. Trade ideas: A short position from 1.15 to 0.5 makes .65 cents/share in short time frame.

User Image kwintz Posted - 1 day ago

$PSTV free money short $$$ 🤑 Offering coming up likely in 2024. Delisting or reverse split in q1 2025. Price will drop 50% minimum from here or company will go extinct. Short with both hands.

User Image Kcmule Posted - 1 day ago

$PSTV Back to fresh 52 week lows

User Image kwintz Posted - 1 day ago

$PSTV shorts going all in on delisting

User Image kwintz Posted - 1 day ago

$PSTV All time lows within days, offering before end of year.

User Image Runner_G Posted - 1 day ago

$PSTV Do not buy until leadership communicates delisting alleviation action plan.

User Image kwintz Posted - 1 day ago

$PSTV offering before end of year. Reverse split or delisting q1 2025.

User Image kwintz Posted - 1 day ago

$PSTV sub $1 coming in hot

User Image CrumbCatchin Posted - 1 day ago

$PSTV https://www.globenewswire.com/news-release/2024/11/22/2985887/0/en/Plus-Therapeutics-to-Present-Positive-FORESEE-Clinical-Trial-Summary-Demonstrating-Utility-of-CNSide-Cerebrospinal-Fluid-Assay-in-Diagnosis-and-Clinical-Management-of-Patients-with.html

User Image JimBull Posted - 1 day ago

$PSTV low float with good news:

User Image MrTicker Posted - 1 day ago

$PSTV Plus Therapeutics Subsidiary CNSide Diagnostics To Present Data From FORESEE Trial AT SNO Meeting; CNSide Cerebrospinal Fluid Assay Met Key Primary And Secondary Endpoints BENZINGA 6:33 AM ET 11/22/2024

User Image Iman133 Posted - 3 days ago

$PSTV If nobody buys, then shorts are selling to who? Ghosts?

User Image kwintz Posted - 3 days ago

$PSTV not a single person buying. Only shorts adding to positions. Will be sub $1 soon. See you after offering and reverse split!

User Image CrumbCatchin Posted - 4 days ago

$PSTV Was that a SL check before liftoff?

User Image Runner_G Posted - 4 days ago

$PSTV Prediction for this week (and after): A continued price drop into the SNO 2024 meeting where PSTV will share non-material data and drive discussions (this happens many times/year). Price appreciation after the non-material updates are released, followed by an immediate, significant sell-off that will ultimately lead through the remainder of 2024. There are no more material milestones in 2024. Even the PBC IND was pushed to 2025 (no surprise). Delisting status continues to be a red flag. Most likely plan of action indicates offering + reverse split to maintain listing. Recommendation: Wait until leadership can clearly communicate their plan to regain NASDAQ listing requirements. It will likely come at a detriment to current pricing/shareholder value.

User Image vaselineguy Posted - 5 days ago

$PSTV volume traded 🤣🤣🤣🤣🤣🤣 @plustherapeutics please go to OTC

User Image kwintz Posted - 5 days ago

$PSTV serial pumper below. Pumped ER before the 10% loss and now pumping another PowerPoint conference that delivers 0 results. See you under $1

User Image Zaneyone Posted - 5 days ago

$XBI $BBI $SLS $PSTV - Buy - PT $8/share. Quote: "Furthermore, significant clinical advancements are anticipated at the forthcoming Society of Neuro-Oncology meeting. The updated results from the Phase 1 ReSPECT-LM study could potentially affirm the efficacy and tolerability of their treatment for leptomeningeal metastasis, which would be a crucial milestone for Plus Therapeutics. Additionally, the company is commercializing its CNSide assay, which is considered a leading diagnostic tool for LM. With regulatory approvals in place and strategic plans for commercialization, Plus Therapeutics is poised to leverage its innovations effectively in the market..." from "Plus Therapeutics: Promising Growth and Stability Backed by Financial Strength and Clinical Innovations..." ***Excellent buy in point at 1 year lows/previously tested support. Ideal M&A target/bull run after new medical device application PR released (Rhenium 188 4 liver cancer). MB$ pipeline! https://www.tipranks.com/news/blurbs/plus-therapeutics-promising-growth-and-stability-backed-by-financial-strength-and-clinical-innovations?

User Image Iman133 Posted - 5 days ago

$PSTV You are late today. Your boss will be angry!

User Image RookieTrader500 Posted - 1 week ago

$PSTV pstvq can’t wait

User Image vaselineguy Posted - 1 week ago

$PSTV hi mo @joka2189 what happened with see you above 20 lmao (300 now post reverse split) the hungry earner the grid player the retarded one. Pathetic.

User Image vaselineguy Posted - 1 week ago

$PSTV @plustherapeutics

User Image vaselineguy Posted - 1 week ago

$PSTV horrible company, scam ceo and clown shareholders

User Image kwintz Posted - 1 week ago

$PSTV All time lows here next week, put your banking hats on! Have a good weekend

Analyst Ratings
HC Wainwright & Co. Buy Aug 16, 24
HC Wainwright & Co. Buy Aug 15, 23
HC Wainwright & Co. Buy Aug 14, 23
HC Wainwright & Co. Buy Jun 30, 23
Maxim Group Buy May 3, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
HEDRICK MARC H Chief Executive Offi.. Chief Executive Officer Nov 20 Sell 1.9597 2,068 4,053 170 12/15/23
Lenk Robert P Director Director Nov 15 Buy 1.86 2,000 3,720 25,160 11/17/23
Lenk Robert P Director Director Nov 08 Buy 1.62 9,199 14,902 17,160 11/13/23
Lenk Robert P Director Director Nov 06 Buy 1.57 7,395 11,610 7,961 11/08/23
Clowes Howard Director Director Sep 13 Buy 1.4331 6,993 10,022 11,693 09/15/23
Petersen Greg Director Director Sep 11 Buy 1.7031 20,000 34,062 24,166 09/12/23
Clowes Howard Director Director Jun 06 Buy 3.98 1,000 3,980 4,700 06/08/23
Clowes Howard Director Director May 03 Buy 3.6406 2,500 9,102 3,700 05/04/23
Hawkins Richard J Director Director Mar 03 Buy 1000.00 1 1,000 1 03/06/23
HEDRICK MARC H Chief Executive Offi.. Chief Executive Officer Jun 15 Buy 0.648 5,000 3,240 33,580 06/16/22
Clowes Howard Director Director Jun 02 Buy 0.5726 15,000 8,589 18,000 06/06/22
HEDRICK MARC H Chief Executive Offi.. Chief Executive Officer Apr 27 Buy 0.6841 2,500 1,710 28,580 04/28/22
Sims Andrew John Hugh MacIntyr... Chief Financial Offi.. Chief Financial Officer Apr 26 Buy 0.672 3,000 2,016 12,230 04/27/22
HEDRICK MARC H Chief Executive Offi.. Chief Executive Officer Apr 26 Buy 0.69 5,000 3,450 26,080 04/27/22
Sims Andrew John Hugh MacIntyr... Chief Financial Offi.. Chief Financial Officer Mar 01 Buy 1.0999 2,000 2,200 9,230 03/03/22
Sims Andrew John Hugh MacIntyr... Chief Financial Offi.. Chief Financial Officer Jul 29 Buy 1.98 4,230 8,375 4,230 07/29/21